Editorial Board About Us

Samir S Taneja

All articles from this author are listed below.

Volume 5, Supplement 2 Supplement

A Multidisciplinary Approach to the Management of Hormone-Refractory Prostate Cancer

Prostate cancer Androgen-insensitive Hormone-refractory Multidisciplinary

Volume 5, Supplement 3 Supplement

A Multidisciplinary Approach to the Management of Hormone-Refractory Prostate Cancer

Prostate cancer Androgen-insensitive Hormone-refractory Multidisciplinary

Volume 5, Number 3 Review Articles

Optimizing Prostate Biopsy Strategies for the Diagnosis of Prostate Cancer

Technique Review

Prostate cancer Prostate biopsy Transrectal ultrasound

Volume 6, Supplement 10 Supplement

ProstaScint Scan: Contemporary Use in Clinical Practice

Prostate cancer Staging ProstaScint

Volume 6, Number 3 Review Articles

Imaging in the Diagnosis and Management of Prostate Cancer

Treatment Update

Prostate cancer ProstaScint MRI MRSI Combidex

Volume 7, Supplement 3 Review Articles

Drug Therapies for Eradicating High-Grade Prostatic Intraepithial Neoplasia in the Prevention of Prostate Cancer

Prostate cancer Selective estrogen receptor modulator Chemoprevention High-grade prostatic intraepithelial neoplasia Estrogen Toremifene

Volume 8, Number 4 Review Articles

Prostate Biopsy: Targeting Cancer for Detection and Therapy

Technology Update

Despite improvements in cancer detection, prostate biopsy still lacks the ability to accurately map locations of cancer within the prostate. Improvements in prostate imaging may allow more accurate mapping of overall disease volume. Magnetic resonance (MR) spectroscopy allows improved specificity in detecting even small foci of disease within the peripheral zone. Improvements in MR-guided biopsy techniques may allow this technology to be adapted to therapeutics as well. Computer modeling of individual prostates serves as a means of designing optimized plans for prostate biopsy. The use of novel targeted biopsy schemes may allow an integration of available technologies in detection and localization of prostate cancer. Computer-directed needle biopsies based on anatomic landmarks within the prostate and computerized three-dimensional reconstruction of the gland may allow a highly reproducible means of identifying small foci of cancer, targeting them for therapy, and monitoring for recurrence. The TargetScan® system (Envisioneering Medical Technologies, St. Louis, MO) is the first technology to integrate available targeting methodologies in a systematic fashion. [Rev Urol. 2006;8(4):173-182]

Prostate cancer Biopsy Transrectal ultrasound 3D mapping

Volume 11, Number 4 Review Articles

Focal Therapy: A New Paradigm for the Treatment of Prostate Cancer

Treatment Update

Guilherme Godoy Basir Tareen Samir S Taneja

Focal therapy has been proposed in recent years as a means of bridging the gap between radical prostatectomy and active surveillance for treatment of prostate cancer. The rationale for focal therapy comes from its success in treating other malignancies. One of the challenges in applying such an approach to the treatment of prostate cancer has been the multifocal nature of the disease. This review addresses the selection of potentially ideal candidates for focal therapy and discusses which modalities are currently being used and proposed for focal therapy. Setting and meeting guidelines for oncologic efficacy is a challenge we must embrace to safely deliver this potentially revolutionary approach to treating men with prostate cancer.[Rev Urol. 2009;11(4):203-212 doi: 10.3909/riu0475]© 2009 MedReviews®, LLC

Prostatic neoplasms Focal therapy Prostate-specific antigen Prostatectomy Photodynamic therapy Ultrasound, high-inten sity focused, transrectal Cryosurgery

Volume 11, Number 3 Review Articles

Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials

Management Update

Markus Margreiter Helen Sadri Julia Finkelstein Elisabeth Eckersberger Bob Djavan Herbert Lepor Samir S Taneja

The advent of prostate-specific antigen (PSA) testing in the early 1980srevolutionized the diagnosis of prostate cancer. As a result of PSA testing,there has been a surge in the number of prostate cancer diagnoses. Thisreview examines the results of 2 recent landmark trials that studied the effectof screening on prostate cancer mortality: the European Randomized Study ofScreening for Prostate Cancer (ERSPC) and the US-based Prostate, Lung,Colorectal, and Ovarian (PLCO) Cancer Screening Trial.[Rev Urol. 2009;11(3):127-133 doi: 10.3909/riu0474]

PSA screening European Randomized Study of Screening for Prostate Cancer(ERSPC)Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

Volume 11, Number 1 Case Review

Renal Involvement by Chronic Myelomonocytic Leukemia Requiring Nephroureterectomy

Jonathan Melamed Raavi Gupta Elias S Hyams Ojas D Shah Samir S Taneja

Chronic monomyelocytic leukemia (CMML) is a relatively rare clonal hematologic disorder with features of myelodysplastic syndrome and myeloproliferative disease. Renal impairment from CMML is infrequent and can result from both direct (ie, infiltrative) and indirect (eg, vasculitis, infarction) mechanisms. This case report describes a patient with refractory gross hematuria requiring nephroureterectomy with diffuse involvement of the upper tract by CMML and accompanying extramedullary hematopoiesis. Underscored are the need to maintain a broad differential diagnosis for upper tract lesions in the setting of gross hematuria, and the potential need for drastic measures to control upper tract bleeding if conservative measures fail.[Rev Urol. 2009;11(1):33-37]

Gross hematuria Secondary malignancy of kidney Leukemia